NASDAQ:ACLX

Arcellx stock sticks near $115 after Gilead bid — what could move ACLX next

Gilead agreed to acquire Arcellx for $115 per share in cash plus a $5 contingent payout tied to anito-cel sales. Arcellx closed flat at $113.75 Tuesday, just below the offer price, and traded at $113.70 after hours. The tender offer remains subject to antitrust review and FDA approval, with a PDUFA date set for Dec. 23, 2026. Gilead shares slipped 1% on the day.

25 February 2026

NASDAQ:ACLX·NASDAQ:GILD·Stock Market

Arcellx stock steadies near $115 after Gilead’s $7.8 billion takeover bid — what traders watch next

Arcellx shares traded at $113.86 Tuesday after Gilead Sciences agreed to buy the company for $115 per share in cash plus a $5 contingent value right tied to anito-cel sales. The $7.8 billion deal awaits a tender offer launch and regulatory approvals, with the FDA’s decision on anito-cel expected by December 23, 2026.

24 February 2026

NASDAQ:ACLX·NASDAQ:GILD·Stock Market

Arcellx stock jumps 78% on Gilead’s $7.8 billion buyout — deal terms, risks and next catalyst

Arcellx shares jumped 77.6% to $113.84 after Gilead Sciences agreed to buy the company for $115 per share in cash plus a contingent value right tied to anito-cel sales. The deal came as U.S. stocks fell on new 15% global tariffs announced by President Trump. Gilead shares slipped 0.6%. Investors are watching the FDA’s Dec. 23, 2026 review deadline for anito-cel, a CAR-T therapy for multiple myeloma.

23 February 2026

NASDAQ:ACLX·NASDAQ:GILD·Stock Market

Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx shares surged 78% to $113.92 after Gilead Sciences agreed to acquire the company for $115 per share in cash, plus a $5 contingent payout tied to anito-cel sales, valuing Arcellx at up to $7.8 billion. The companies expect to close the deal in Q2 2026. Trading volume in Arcellx topped 11 million shares by mid-morning. Gilead shares fell 0.5%.

23 February 2026

NASDAQ:ACLX·NASDAQ:GILD·NASDAQ:LEGN·NYSE:JNJ·Stock Market

Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025

Arcellx shares closed at $72.08 on December 9, down 2.7% after surging 13.6% pre-market on positive Phase 2 data for its multiple myeloma therapy anito-cel at ASH 2025. The iMMagine-1 study showed a 96% overall response rate and no delayed neurotoxicities in 117 heavily pretreated patients. Analysts maintain a “Strong Buy” consensus and anticipate a 2026 commercial launch.

9 December 2025

Biotechnology·NASDAQ:ACLX·Stock Market

Kennametal (KMT) Valuation Examined After Recent Share Price Decline
March 20, 2026, 3:19 AM EDT. Kennametal (KMT) shares fell about 9% last week and 10% over the month following a strong 22% gain in three months. Despite a 67.9% total shareholder return over one year, recent pullbacks raise questions on future growth prospects. The stock trades slightly below analyst targets but well below some intrinsic value estimates, with a fair value around $37.13 versus a $35.18 close. Cost-cutting efforts, including $125 million in expected savings by fiscal 2028, aim to improve margins. However, risks include persistent weak demand and potential delay in realizing efficiencies. Investors should weigh these factors carefully amid mixed market signals and consider alternative industrial exposure opportunities.